Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease

Journal of Virology

Volumn 89, Issue 3, 2015, Pages 1564-1578

  Su, Yung Chang ^a,b   Townsend, Dijana ^b,c   Herrero, Lara J ^a,b   Zaid, Ali ^b   Rolph, Michael S ^a,b   Gahan, Michelle E ^b   Nelson, Michelle A ^b   Rudd, Penny A ^a   Matthaei, Klaus I ^c   Foster, Paul S ^d   Dent, Lindsay ^e   Tripp, Ralph A ^f   Lee, James ^g   Simson, Ljubov ^b   Mahalingam, Suresh ^a,b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF CANBERRA   (Australia)

^c Biology and Environment   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF GEORGIA   (United States)

^g MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; INTERLEUKIN 5; NITRIC OXIDE SYNTHASE; RANTES; RESPIRATORY SYNCYTIAL VIRUS VACCINE; INACTIVATED VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; EOSINOPHIL; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IN VIVO STUDY; LOEFFLER PNEUMONIA; LUNG LAVAGE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT ALLERGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH2 CELL; VIRAL CLEARANCE; VIRUS STRAIN; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; PATHOLOGY; TRANSGENIC MOUSE; VIROLOGY; VIRUS LOAD;

ANIMALIA; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; EOSINOPHILS; FEMALE; LUNG; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, INACTIVATED; VIRAL LOAD;

EID: 84921501593     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01536-14     Document Type: Article

References (70)

1. Couch RB, Englund JA, Whimbey E. 1997. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 102:2-9.
2. Ebbert JO, Limper AH. 2005. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration 72:263-269. http://dx.doi.org/10.1159/000085367.
3. Falsey AR. 1998. Respiratory syncytial virus infection in older persons. Vaccine 16:1775-1778. http://dx.doi.org/10.1016/S0264-410X(98)00142-X.
4. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. NEngl J Med 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
5. Openshaw PJ. 2002. Potential therapeutic implications of new insights into respiratory syncytial virus disease. Respir Res 3(Suppl 1):S15-S20. http://dx.doi.org/10.1186/rr184.
6. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446. http://dx.doi.org/10.1001/jama.282.15.1440.
7. Lemanske RF. 2004. Viral infections and asthma inception. J Allergy Clin Immunol 114:1023-1026. http://dx.doi.org/10.1016/j.jaci.2004.08.031.
8. Potash L, Tytell AA, Sweet BH, Machlowitz RA, Stokes J, Jr, Weibel RE, Woodhour AF, Hilleman MR. 1966. Respiratory virus vaccines. I. Respiratory syncytial and parainfluenza virus vaccines. Am Rev Respir Dis 93:536-548.
9. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89:405-421.
10. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422-434.
11. Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, Sewell HF, Milner AD. 1994. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 71:428-432. http://dx.doi.org/10.1136/adc.71.5.428.
12. Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, Rosenberg HF, Foster PS, Matthaei KI. 2007. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 110:1578-1586. http://dx.doi.org/10.1182/blood-2007-01-071340.
13. Castilow EM, Meyerholz DK, Varga SM. 2008. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccineenhanced disease. J Immunol 180:2376-2384. http://dx.doi.org/10.4049/jimmunol.180.4.2376.
14. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, III, Murphy BR. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68:5321-5325.
15. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC, III, Sotnikov AV, Murphy BR. 1992. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSVimmunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66:7444-7451.
16. Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N, Graham BS. 1997. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15:525-532. http://dx.doi.org/10.1016/S0264-410X(97)00218-1.
17. Johnson TR, Graham BS. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73:8485-8495.
18. Johnson TR, Rothenberg ME, Graham BS. 2008. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4 T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leukoc Biol 84:748-759. http://dx.doi.org/10.1189/jlb.0907621.
19. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. 2003. Enhanced disease and pulmonary eosinophilia associated with formalininactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 77:9831-9844. http://dx.doi.org/10.1128/JVI.77.18.9831-9844.2003.
20. Haynes LM, Tonkin J, Anderson LJ, Tripp RA. 2002. Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol 76:6873-6881. http://dx.doi.org/10.1128/JVI.76.14.6873-6881.2002.
21. Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P. 1997. Targeted disruption of the chemokine eotaxin partially reduces antigeninduced tissue eosinophilia. J Exp Med 185:785-790. http://dx.doi.org/10.1084/jem.185.4.785.
22. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Köhler G, Young IG, Matthaei KI. 1996. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4:15-24. http://dx.doi.org/10.1016/S1074-7613(00)80294-0.
23. Dent LA. 2002. For better or worse: common determinants in immunity and inflammatory diseases, homeostasis and reproduction. J Reprod Immunol 57:255-272. http://dx.doi.org/10.1016/S0165-0378(02)00017-7.
24. Dent LA, Strath M, Mellor A, Sanderson CJ. 1990. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 172:1425-1431. http://dx.doi.org/10.1084/jem.172.5.1425.
25. Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, Foster PS, Rothenberg ME. 2001. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 108:594-601. http://dx.doi.org/10.1067/mai.2001.118600.
26. Peebles RS, Jr, Sheller JR, Collins RD, Jarzecka K, Mitchell DB, Graham BS. 2000. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis 182:671-677. http://dx.doi.org/10.1086/315783.
27. Rolph MS, Mahalingam S, Cowden WB. 2004. Nonspecific antiviral immunity by formalin-fixed Coxiella burnetii is enhanced in the absence of nitric oxide. Virology 326:1-5. http://dx.doi.org/10.1016/j.virol.2004.04.049.
28. Mattes J, Yang M, Mahalingam S, Kuehr J, Webb DC, Simson L, Hogan SP, Koskinen A, McKenzie AB, Dent LA, Rothenberg ME, Matthaei KI, Young IG, Foster PS. 2002. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 195:1433-1444. http://dx.doi.org/10.1084/jem.20020009.
29. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, Buonsanti C, Miotto D, Mapp C, Villa A, Arrigoni G, Fabbri LM, Sinigaglia F. 2001. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 107:1357-1364. http://dx.doi.org/10.1172/JCI12655.
30. Yang M, Rangasamy D, Matthaei KI, Frew AJ, Zimmermann N, Mahalingam S, Webb DC, Tremethick DJ, Thompson PJ, Hogan SP, Rothenberg ME, Cowden WB, Foster PS. 2006. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J Immunol 177:5595-5603. http://dx.doi.org/10.4049/jimmunol.177.8.5595.
31. Su YC, Rolph MS, Cooley MA, Sewell WA. 2006. Cyclophosphamide augments inflammation by reducing immunosuppression in a mouse model of allergic airway disease. J Allergy Clin Immunol 117:635-641. http://dx.doi.org/10.1016/j.jaci.2005.10.042.
32. Su YC, Rolph MS, Hansbro NG, Mackay CR, Sewell WA. 2008. Granulocyte-macrophage colony-stimulating factor is required for bronchial eosinophilia in a murine model of allergic airway inflammation. J Immunol 180:2600-2607. http://dx.doi.org/10.4049/jimmunol.180.4.2600.
33. Yang M, Hogan SP, Mahalingam S, Pope SM, Zimmermann N, Fulkerson P, Dent LA, Young IG, Matthaei KI, Rothenberg ME, Foster PS. 2003. Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia hyperreactivity. J Allergy Clin Immunol 112:935-943. http://dx.doi.org/10.1016/j.jaci.2003.08.010.
34. Sharkhuu T, Matthaei KI, Forbes E, Mahalingam S, Hogan SP, Hansbro PM, Foster PS. 2006. Mechanisms of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity. Clin Exp Allergy 36:1575-1583. http://dx.doi.org/10.1111/j.1365-2222.2006.02595.x.
35. Huffnagle GB, Boyd MB, Street NE, Lipscomb MF. 1998. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 160:2393-2400.
36. Wang J, Palmer K, Lotvall J, Milan S, Lei XF, Matthaei KI, Gauldie J, Inman MD, Jordana M, Xing Z. 1998. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 102:1132-1141. http://dx.doi.org/10.1172/JCI2686.
37. Wardlaw AJ. 1999. Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol 104:917-926. http://dx.doi.org/10.1016/S0091-6749(99)70069-2.
38. Romagnani S. 1994. Regulation of the development of type 2 T-helper cells in allergy. Curr Opin Immunol 6:838-846. http://dx.doi.org/10.1016/0952-7915(94)90002-7.
39. Kanda A, Driss V, Hornez N, Abdallah M, Roumier T, Abboud G, Legrand F, Staumont-Salle D, Queant S, Bertout J, Fleury S, Remy P, Papin JP, Julia V, Capron M, Dombrowicz D. 2009. Eosinophil-derived IFN-gamma induces airway hyperresponsiveness and lung inflammation in the absence of lymphocytes. J Allergy Clin Immunol 124:573-582. http://dx.doi.org/10.1016/j.jaci.2009.04.031.
40. Culley FJ, Pennycook AM, Tregoning JS, Dodd JS, Walzl G, Wells TN, Hussell T, Openshaw PJ. 2006. Role of CCL5 (RANTES) in viral lung disease. J Virol 80:8151-8157. http://dx.doi.org/10.1128/JVI.00496-06.
41. Monick MM, Powers LS, Hassan I, Groskreutz D, Yarovinsky TO, Barrett CW, Castilow EM, Tifrea D, Varga SM, Hunninghake GW. 2007. Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. J Immunol 179:1648-1658. http://dx.doi.org/10.4049/jimmunol.179.3.1648.
42. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, Newman W, Gerard C, Mackay CR. 1996. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183:2437-2448. http://dx.doi.org/10.1084/jem.183.6.2437.
43. Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, Yoshie O, Hirai K. 2000. Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 165:2205-2213. http://dx.doi.org/10.4049/jimmunol.165.4.2205.
44. Berin MC, Eckmann L, Broide DH, Kagnoff MF. 2001. Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts. Am J Respir Cell Mol Biol 24:382-389. http://dx.doi.org/10.1165/ajrcmb.24.4.4360.
45. Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY, Nguyen TN. 2001. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J Virol 75:12421-12430. http://dx.doi.org/10.1128/JVI.75.24.12421-12430.2001.
46. Mould AW, Ramsay AJ, Matthaei KI, Young IG, Rothenberg ME, Foster PS. 2000. The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. J Immunol 164:2142-2150. http://dx.doi.org/10.4049/jimmunol.164.4.2142.
47. Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ. 2005. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol 79:2050-2057. http://dx.doi.org/10.1128/JVI.79.4.2050-2057.2005.
48. Mould AW, Matthaei KI, Young IG, Foster PS. 1997. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 99:1064-1071. http://dx.doi.org/10.1172/JCI119234.
49. Hogan SP, Koskinen A, Matthaei KI, Young IG, Foster PS. 1998. Interleukin-5-producing CD4 T cells play a pivotal role in aeroallergeninduced eosinophilia, bronchial hyperreactivity, and lung damage in mice. Am J Respir Crit Care Med 157:210-218. http://dx.doi.org/10.1164/ajrccm.157.1.9702074.
50. Mattes J, Foster PS. 2003. Regulation of eosinophil migration and Th2 cell function by IL-5 and eotaxin. Curr Drug Targets Inflamm Allergy 2:169-174. http://dx.doi.org/10.2174/1568010033484214.
51. Johnson TR, Varga SM, Braciale TJ, Graham BS. 2004. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol 78:8753-8760. http://dx.doi.org/10.1128/JVI.78.16.8753-8760.2004.
52. Hamelmann E, Wahn U, Gelfand EW. 1999. Role of the Th2 cytokines in the development of allergen-induced airway inflammation and hyperresponsiveness. Int Arch Allergy Immunol 118:90-94. http://dx.doi.org/10.1159/000024037.
53. Kelly BL, Locksley RM. 2000. Coordinate regulation of the IL-4, IL-13, and IL-5 cytokine cluster in Th2 clones revealed by allelic expression patterns. J Immunol 165:2982-2986. http://dx.doi.org/10.4049/jimmunol.165.6.2982.
54. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. 1996. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183:195-201. http://dx.doi.org/10.1084/jem.183.1.195.
55. Huang TJ, MacAry PA, Eynott P, Moussavi A, Daniel KC, Askenase PW, Kemeny DM, Chung KF. 2001. Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma. J Immunol 166:207-217. http://dx.doi.org/10.4049/jimmunol.166.1.207.
56. Weigt H, Nassenstein C, Tschernig T, Muhlradt PF, Krug N, Braun A. 2005. Efficacy of macrophage-activating lipopeptide-2 combined with interferon-gamma in a murine asthma model. Am J Respir Crit Care Med 172:566-572. http://dx.doi.org/10.1164/rccm.200411-1490OC.
57. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. 1992. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 176:1489-1495. http://dx.doi.org/10.1084/jem.176.6.1489.
58. Koya T, Takeda K, Kodama T, Miyahara N, Matsubara S, Balhorn A, Joetham A, Dakhama A, Gelfand EW. 2006. RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge. Am J Respir Cell Mol Biol 35:147-154. http://dx.doi.org/10.1165/rcmb.2005-0394OC.
59. Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin TS, Hancock GE. 2004. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5). J Med Virol 73:300-308. http://dx.doi.org/10.1002/jmv.20091.
60. Domachowske JB, Bonville CA, Dyer KD, Rosenberg HF. 1998. Evolution of antiviral activity in the ribonuclease A gene superfamily: evidence for a specific interaction between eosinophil-derived neurotoxin (EDN/RNase 2) and respiratory syncytial virus. Nucleic Acids Res 26:5327-5332. http://dx.doi.org/10.1093/nar/26.23.5327.
61. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. 1998. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 177:1458-1464. http://dx.doi.org/10.1086/515322.
62. Rosenberg HF, Dyer KD, Domachowske JB. 2009. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res 83:1-9. http://dx.doi.org/10.1016/j.antiviral.2009.04.005.
63. Shamri R, Melo RC, Young KM, Bivas-Benita M, Xenakis JJ, Spencer LA, Weller PF. 2012. CCL11 elicits secretion of RNases from mouse eosinophils and their cell-free granules. FASEB J 26:2084-2093. http://dx.doi.org/10.1096/fj.11-200246.
64. Garofalo R, Kimpen JL, Welliver RC, Ogra PL. 1992. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 120:28-32. http://dx.doi.org/10.1016/S0022-3476(05)80592-X.
65. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. 1999. Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. AmJ Respir Crit Care Med 159:1918-1924. http://dx.doi.org/10.1164/ajrccm.159.6.9805083.
66. Filley WV, Holley KE, Kephart GM, Gleich GJ. 1982. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet ii:11-16.
67. Gleich GJ. 2000. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105:651-663. http://dx.doi.org/10.1067/mai.2000.105712.
68. Kampen GT, Stafford S, Adachi T, Jinquan T, Quan S, Grant JA, Skov PS, Poulsen LK, Alam R. 2000. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogenactivated protein kinases. Blood 95:1911-1917.
69. Olszewska-Pazdrak B, Pazdrak K, Ogra PL, Garofalo RP. 1998. Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. J Immunol 160:4889-4895.
70. Percopo CM, Dyer KD, Ochkur SI, Luo JL, Fischer ER, Lee JJ, Lee NA, Domachowske JB, Rosenberg HF. 2014. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood 123:743-752. http://dx.doi.org/10.1182/blood-2013-05-502443.